FOXD2 and neoplasm: Specifically, Li et al. showed that FOXD2-AS1 displayed a tumor-specific upregulation (compared to paired adjacent normal; ~2-fold increase; N = 24 cases), and its upregulation was further found to be associated with disease relapse upon cisplatin-based chemotherapy in a small HNC cohort (N = 14 cases, 9 cases with relapse and 5 cases without relapse), which uncovered the direct involvement of FOXD2-AS1 in mediating cisplatin resistance in HNC.